Caspofungin—a new therapeutic option for oropharyngeal candidiasis

This publication has 17 references indexed in Scilit:

• Efficacy of Caspofungin in the Treatment of Esophageal Candidiasis Resistant to Fluconazole
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
• In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance
  Journal of Clinical Microbiology, 2002
• Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases
  Antimicrobial Agents and Chemotherapy, 2002
• A Randomized Double‐Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal Esophagitis
  Clinical Infectious Diseases, 2001
• Determinants for the Development of Oropharyngeal Colonization or Infection by Fluconazole-Resistant Candida Strains in HIV-Infected Patients
  European Journal of Clinical Microbiology & Infectious Diseases, 2000
• Epidemiology of Human Immunodeficiency Virus–Associated Opportunistic Infections in the United States in the Era of Highly Active Antiretroviral Therapy
  Clinical Infectious Diseases, 2000
• Practice Guidelines for the Treatment of Candidiasis
  Clinical Infectious Diseases, 2000
• Current and future antifungal therapy: new targets for antifungal agents
  Journal of Antimicrobial Chemotherapy, 1999
• Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection
  Clinical Infectious Diseases, 1998
• In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
  Antimicrobial Agents and Chemotherapy, 1997